I’m heavily skewed to the company that has a chance to go 5x, 10x in the next 12-18 months off organic progress (could have one approved product in the US by end of this year and a second approved product in the US market by end of next year) .. with potential to go 20x or more if their blockbuster product hits the confirmatory phase 3 trial which is about to start recruiting.
there is always the chance of some M&A action, but I don’t invest based on that.
for IMU I am here to buy the dips over the next few years… and get a nice average. Still a long runway, and happy to pay more if clinical outcomes justify it.
Media Thread, page-13404
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.1¢ | $1.607M | 38.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 4542680 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1675759 | 9 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |